Aligos Therapeutics Inc (ALGS) — Cash Flow-to-Debt Ratio
Aligos Therapeutics Inc (ALGS) has a Cash Flow-to-Debt Ratio of -0.71x as of March 2026, meaning its operating cash flow of $-23.13 Million could theoretically repay -1% of its total liabilities ($32.77 Million) in one year. See Aligos Therapeutics Inc (ALGS) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aligos Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Aligos Therapeutics Inc across 8 annual periods. Also explore Aligos Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aligos Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Aligos Therapeutics Inc. For market capitalisation and broader financial context, see how much is Aligos Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.36x | $-82.50 Million | $34.99 Million | ▼ -189.3% |
| 2024 | -0.82x | $-80.74 Million | $99.07 Million | ▲ +38.7% |
| 2023 | -1.33x | $-79.00 Million | $59.45 Million | ▲ +28.4% |
| 2022 | -1.86x | $-79.39 Million | $42.79 Million | ▲ +18.8% |
| 2021 | -2.28x | $-115.66 Million | $50.64 Million | ▼ -39.2% |
| 2020 | -1.64x | $-74.26 Million | $45.26 Million | ▼ -641.7% |
| 2019 | -0.22x | $-46.77 Million | $211.41 Million | ▼ -344.3% |
| 2018 | -0.05x | $-6.05 Million | $121.48 Million | — |